ArticleCureus2026
Acute Pancreatitis Complicating L-asparaginase Therapy in Pediatric Oncology: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute pancreatitis is a recognized toxicity of L-asparaginase therapy during the treatment of pediatric acute lymphoblastic leukemia (ALL). Its management requires a delicate balance between avoiding leukemic relapse and preventing pancreatic recurrence. We report the case of a five-year-and-eight-month-old girl with Philadelphia chromosome-positive B-cell ALL, initially treated with imatinib combined with the high-risk MARALL 2006 protocol, and subsequently with the COOPRALL 97 protocol following an isolated central nervous system relapse. Seventy-two hours after the 18th cumulative administration of L-asparaginase, she developed epigastric pain and vomiting. Serum lipase was greater than three times the upper limit of normal, confirming the diagnosis of acute pancreatitis. The episode was classified as grade 2 according to the Ponte di Legno group classification. After clinical and biological resolution of pancreatitis, L-asparaginase was reintroduced because of the patient's high-risk relapsed leukemia. After 10 weeks of follow-up after reintroduction, no recurrence was observed. This case supports the feasibility of L-asparaginase rechallenge in selected high-risk pediatric patients following a multidisciplinary risk-benefit assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.